

Votrient[®] (pazopanib) – First-time generic

- On October 20, 2023, [Sun Pharma](#) and [Teva](#) launched [AB-rated](#) generic versions of Novartis' [Votrient \(pazopanib\)](#) tablets.
- Votrient is approved for the treatment of adults with advanced renal cell carcinoma and advanced soft tissue sarcoma who have received prior chemotherapy.